Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Debiopharm honors cancer research in Lausanne

11.10.2006
The first Debiopharm Life Sciences Award will be presented to Spanish researcher Dr. Eduard Batlle during the 6th annual ISREC cancer research conference in Lausanne, Switzerland. This young scientist and his institute will receive 100,000 francs for his outstanding contributions to cancer research.

The award will be presented Wednesday, October 11, as part of the conference co-organized by EPFL (Ecole Polytechnique Federale deLausanne) and ISREC (Swiss Institute for Experimental Cancer Research) and held on the EPFL campus.

With one foot firmly in fundamental research and the other in clinical work, Eduard Batlle has concentrated his efforts over the past decade on elucidating the mechanisms underlying the onset and progression of colorectal cancer. His independent research in three different areas of colorectal cancer – the study of intestinal stem cells and their malignant counterparts, identification of molecules that prevent malignancy of colorectal tumors, and identification of the genetic components involved in the spread of cancer cells to the liver -- represents an important contribution to our understanding of this deadly cancer. His published articles have been cited more than a thousand times, appearing in journals such as Nature, Nature Cell Biology and Cell. He is also the holder of a patent that is currently being commercially developed by two companies.

Since 2004, Eduard Batlle has led the oncology group at Barcelona’s Biomedical Research Institute (IRB) and is a professor in the Catalan Institute for Research and Advanced Studies. He held postdoctoral research positions in Germany at the University of Marburg and in the Hubrecht Laboratory of the Netherlands Institute for Developmental Biology. He specializes in the areas of molecular biology and colorectal cancer.

POTENTIAL FOR THERAPY

The purpose of the Debiopharm Life Sciences Award is to mentor and motivate innovative European life sciences researchers under the age of 40; this year, the prize is awarded for cancer research. The research must demonstrate innovative vision and originality and have high potential for therapeutic and commercial applications. The jury was composed of three representatives of Debiopharm including Rolland-Yves Mauvernay, the company’s President and Founder; three EPFL professors, including EPFL President Patrick Aebischer; and two external experts. The jury expressed admiration for the « extremely high level » of the candidates.

The Lausanne-based company Debiopharm, founded in 1979, is an independent drug-development company specializing in oncology and serious medical conditions. The company works closely with universities, research institutions, biotech firms or pharmaceutical companies to identify compounds with promising in-vivo results that could lead to new pharmaceutical products. With its considerable expertise and proven track record, Debiopharm shepherds potential products all the way through to the treatment phase. The company is known in particular for having several products such as Eloxatin®, treatment of choice for colorectal cancer, and Decapeptyl® and Trelstar® for prostate cancer treatment. These products are commercialized by pharmaceutical companies such as sanofi-aventis and Watson Pharmaceuticals, Inc.

- For additional information, contact: Dietrich Reinhard, EPFL School of Life Sciences; tel: 021 693 16 43, e-mail: dietrich.reinhard@epfl.ch

- The official presentation ceremony will take place October 11 at 6 :45 pm at EPFL in room SG1, in the presence of Rolland-Yves Mauvernay, Founder and President of Debiopharm and Patrick Aebischer, President of EPFL.

Mary Parlange | alfa
Further information:
http://www.epfl.ch

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>